The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGSKader Cetin Gedik, Raphaela Goldbach‐Mansky, Yanick J. Crow et al.|Annals of the Rheumatic Diseases|2022Cited by 97
The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: <scp>CANDLE</scp>/<scp>PRAAS</scp>, <scp>SAVI</scp>, and <scp>AGS</scp>Kader Cetin Gedik, Raphaela Goldbach‐Mansky, Lovro Lamot et al.|Arthritis & Rheumatology|2022Cited by 48
SARS-CoV-2 mRNA-based vaccines in the Aicardi Goutières SyndromeAsako Takanohashi, Adeline Vanderver, Mohamad‐Gabriel Alameh et al.|Molecular Genetics and Metabolism|2022Cited by 2
mRNA-based vaccines against SARS-CoV-2 do not stimulate interferon stimulatory gene expression in individuals affected by Aicardi Goutières SyndromeAsako Takanohashi, Adeline Vanderver, Mohamad‐Gabriel Alameh et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 1
A novel patient-Centered approach to clinical trial readiness in rare diseases: Application in Aicardi-Goutières Syndrome (AGS)Anjana Sevagamoorthy, Adeline Vanderver, Francesco Gavazzi et al.|Molecular Genetics and Metabolism|2026Cited by 0